




MEDICZEN
G L O B A L

**DATS-3: From Molecular
Discovery to Regenerative
Therapeutic Strategy**

Premature aging diseases and cell damage:

The motivation that made us grow

- Research more than 20 years by a group of prestigious scientists from the CSIC, experts in molecular biology, focused on the research of rare diseases and pathologies related to cell damage caused by oncological diseases.
- They discovered a peptide capable of preventing telomere shortening and extending cell life with a powerful antioxidant, anti-inflammatory and repairing action in aging.
- Our scientific team brought the use of the peptide to its application in dermocosmetics, acting in the protection of telomere length, in cell repair, in the net increase of collagen and, therefore, in the five pillars of aging.
- We maintain all our efforts in R+D to continue the development of formulas to reduce the effect of aging.



- TEAM OF PROFESSIONALS

- **Aesthetic Doctors**
- **Surgeons**
- **Dermatologists**
- **Oncologists**
- **Biologists**
- **Researcher**






The problem / Unmet need

**Daily care of chronic inflammatory skin
pathologies**



Systemic treatment:
corticoids, NSAIDs



Lot of secondary effects



High cost treatment



No cure

The solution

Development of a synthetic battery of peptidemimetic


- Short peptides → Low cost
- Topic application → Less secondary effects
- Improve quality of life
- Scientific development



Zainela Laborde, MD
Paula Pifarré, PhD
Melvis Anaya, MD
Ángel Tapia, MD
Juan Carlos Rondón, PhD



Rosario Perona, PhD
Leandro Sastre, PhD
Marta Gutiérrez, PhD
Mercedes Martin, PhD



From Scientific Development to the Name

DNA protection •
Antioxidant activity •
Telomerase activation •
Stress response modulation

DATS 3

A Molecular Reprogramming Strategies for Tissue Regeneration and Cellular Longevity



International Innovation Recognition

With this peptide, we were selected as finalists at:

- **Celebrate Innovation – Cantabria Labs 2021 Finalist**
- **Innovation Tanks -IMCAS Paris 2022 Finalist**

Recognized for scientific innovation and breakthrough potential in regenerative aesthetic medicine.

Intellectual Property Milestone

In 2025, the peptide was officially granted patent protection, consolidating its scientific innovation and proprietary value.



Future:

Translational Opportunities in Potential Fields

Regenerative Dermo cosmetic

Regenerative Gynecoesthetic

Nutraceuticals

Atopic dermatitis and inflammatory skin diseases

Radiodermatitis and post-oncological tissue damage

Fibrosis-associated tissue remodeling

→ Any pathology sharing **common biological drivers** warrants further investigation.



Potential Routes of Administration – Peptide Platform

The peptide can be formulated for multiple delivery pathways:

- **Topical** (dermal application)
- **Oral**
- **Parenteral** (subcutaneous, intramuscular, intravenous)
- **Intranasal**
- **Inhalation / Intratracheal**
- **Intra-articular**

Depending on formulation strategy and target indication, it can be developed as a cosmetic or pharmaceutical product.



Motivation

DATS-3 was born from the need to move beyond symptomatic aesthetic solutions and address the biological roots of tissue degeneration.

Our motivation is to decode the molecular mechanisms that drive aging, cellular dysfunction, and regenerative decline — and to intervene at the signaling level, not just the surface.

We believe true innovation in aesthetic medicine must be grounded in cellular biology, not trends.



Vision

To position DATS-3 as a next-generation bioactive platform capable of reprogramming tissue behavior through precise molecular signaling.

Our vision is to integrate regenerative science, peptide engineering, and advanced delivery systems into a unified therapeutic strategy — bridging innovation and pharmaceutical rigor.

**DATS-3 is not just a peptide.
It is a biological strategy.**



Dra. Melvis Anaya



Dra. Zainela Laborde



Dra. Paula Pifarré



Dr. Juan Carlos Rondon



Dr. Ángel Tapia